RxDoctor Payments Data

Ernest Gilmore, MD

Internal Medicine · Bartow, FLNPI 1639143399

Payments from drug & device makers

$1,900in general payments, 2019–2025

Across 94 payments — averaging $20.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$695
  • Exact Sciences$184
  • Lilly USA, LLC$166
  • Novo Nordisk$155
  • Dexcom, Inc.$110
  • AbbVie$109
  • plus $481 from 11 others

What the payments were for

  • Food & beverage$1,88699%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,900 in reported general payments places this provider in the 75th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$50,740
Medicare patients
164
Services billed
514

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide66$74,008
OzempicSemaglutide33$48,006
EliquisApixaban46$33,642
XareltoRivaroxaban16$23,174
TrulicityDulaglutide20$21,135
JardianceEmpagliflozin16$16,888
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$8,754
MyrbetriqMirabegron12$5,420
Incruse ElliptaUmeclidinium Bromide13$5,129
Breo ElliptaFluticasone/Vilanterol11$4,405
Atorvastatin Calcium247$2,269
Levothyroxine Sodium172$2,074
Albuterol Sulfate HfaAlbuterol Sulfate86$1,940
Gabapentin87$1,681
Ventolin HfaAlbuterol Sulfate20$1,642

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$166$95,14386 claims
Novo NordiskOzempic$155$48,00633 claims
PfizerEliquis$99$33,64246 claims
GSKTrelegy Ellipta, Incruse Ellipta, Breo Ellipta$41$18,28837 claims
Boehringer IngelheimJardiance$15$16,88816 claims
AbbVieSynthroid$109$1,31328 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Bartow

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →